Fosfomycin for Uncomplicated Lower UTI in Men with Documented Susceptibility
Do not use fosfomycin in men with uncomplicated lower UTI, even if the culture shows susceptibility. Fosfomycin is explicitly recommended only for women with uncomplicated cystitis, and men require longer treatment durations that fosfomycin's single-dose regimen cannot provide 1.
Why Fosfomycin is Contraindicated in Men
Guideline-Based Restrictions
The 2024 European Association of Urology guidelines are unequivocal: fosfomycin trometamol 3g single dose is "recommended only in women with uncomplicated cystitis" 1. The treatment table explicitly separates regimens for women versus men, with fosfomycin appearing only under first-line treatment for women 1.
The FDA labeling reinforces this restriction, stating fosfomycin is "indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women" 2. This is not merely a study population limitation—it reflects fundamental differences in UTI pathophysiology between sexes.
Duration Requirements in Men
Men with lower UTI require 7 days of treatment with trimethoprim-sulfamethoxazole or fluoroquinolones 1. This extended duration accounts for:
- Higher likelihood of prostatic involvement (even when not clinically apparent)
- Greater anatomical complexity requiring longer antimicrobial exposure
- Risk of progression to complicated infection if undertreated
Fosfomycin's single-dose regimen achieves urinary concentrations >128 mg/L for only 24-48 hours 3, which is insufficient for the 7-day exposure needed in male patients.
Appropriate Treatment for Men
First-Line Therapy
Use trimethoprim-sulfamethoxazole 160/800 mg twice daily for 7 days 1. This remains the guideline-recommended first-line agent for men with uncomplicated lower UTI.
Alternative Options
If trimethoprim-sulfamethoxazole is contraindicated or the organism is resistant:
- Fluoroquinolones (ciprofloxacin or levofloxacin) can be prescribed according to local susceptibility patterns 1
- Duration remains 7 days for both alternatives
Critical Pitfall to Avoid
The most common error is assuming that documented susceptibility to fosfomycin justifies its use regardless of patient sex. Susceptibility testing does not override guideline restrictions based on clinical pharmacology and treatment duration requirements. The organism may be killed by fosfomycin in vitro, but the single-dose regimen cannot provide adequate duration of therapy in male urinary tract anatomy 1, 2.
When Culture Results Should Guide Therapy
If the culture shows resistance to trimethoprim-sulfamethoxazole but susceptibility to fosfomycin, you should:
- Select an alternative agent from the susceptibility panel that is appropriate for 7-day therapy in men
- Consider fluoroquinolones if susceptible and local resistance rates are acceptable
- Use beta-lactams (cephalosporins) if susceptibility allows and local E. coli resistance is <20% 1
The culture guides which appropriate agent to use, but does not expand the indication for agents restricted by sex and treatment duration.